Search hospitals > Ohio > Akron
Summa Health System - Akron Campus
Claim this profileAkron, Ohio 44304
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Adenocarcinoma
Conducts research for Recurrence
276 reported clinical trials
7 medical researchers
Summary
Summa Health System - Akron Campus is a medical facility located in Akron, Ohio. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Adenocarcinoma, Recurrence and other specialties. Summa Health System - Akron Campus is involved with conducting 276 clinical trials across 336 conditions. There are 7 research doctors associated with this hospital, such as Bradley T. Clifford, Desiree E. Doncals, Stephen Andrews, MD, and Peter Bittenbender, MD.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderHER2 negative
Stage IV
ER positive
Top PIs
Bradley T. CliffordSumma Health System - Akron Campus1 year of reported clinical research
Studies Cancer
Studies Breast Cancer
17 reported clinical trials
38 drugs studied
Desiree E. DoncalsSumma Health System - Akron Campus3 years of reported clinical research
Studies Cancer
Studies Breast Cancer
7 reported clinical trials
34 drugs studied
Stephen Andrews, MDSumma Health System - Akron Campus2 years of reported clinical research
Studies Cancer
Studies Cervical Cancer
4 reported clinical trials
14 drugs studied
Peter Bittenbender, MDSumma Health5 years of reported clinical research
Studies Heart Failure
Studies Aortic Stenosis
2 reported clinical trials
2 drugs studied
Clinical Trials running at Summa Health System - Akron Campus
Breast Cancer
Squamous Cell Carcinoma
Lung Cancer
Prostate Cancer
Non-Small Cell Lung Cancer
Cancer
Recurrence
Laryngeal Squamous Cell Carcinoma
Oropharyngeal Carcinoma
Prostate Adenocarcinoma
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Hormone Therapy with or without Radiation
for Breast Cancer
This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radiation and endocrine therapy.
Recruiting2 awards Phase 313 criteria
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Summa Health System - Akron Campus?
Summa Health System - Akron Campus is a medical facility located in Akron, Ohio. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Adenocarcinoma, Recurrence and other specialties. Summa Health System - Akron Campus is involved with conducting 276 clinical trials across 336 conditions. There are 7 research doctors associated with this hospital, such as Bradley T. Clifford, Desiree E. Doncals, Stephen Andrews, MD, and Peter Bittenbender, MD.